Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy

Meghali Goswami, Gabrielle T. Prince, Angélique Biancotto, Susan Moir, Lela Kardava, Brian H. Santich, Foo Cheung, Yuri Kotliarov, Jinguo Chen, Rongye Shi, Huizhi Zhou, Hana Golding, Jody Manischewitz, Lisa R. King, Lauren Kunz, Kimberly Noonan, Ivan Borrello, B. Douglas Smith, Christopher S. HouriganJournal of Translational Medicine 2017 · DOI

TL;DR

This study reveals that while T-cell immunity largely recovers in acute myeloid leukemia (AML) patients after chemotherapy, their B-cell immunity remains significantly impaired for up to a year. This B-cell deficiency, characterized by fewer memory cells and an immature repertoire, likely explains the poor response to influenza vaccination and has critical implications for the success of future immunotherapies in AML.

What Problem Does This Paper Address?

Acute myeloid leukemia (AML) is a blood cancer that is often treated with intensive chemotherapy. While chemotherapy can induce remission, it also severely compromises the immune system, increasing the risk of infections and potentially hindering the effectiveness of future treatments like immunotherapy. Specifically, the long-term impact of chemotherapy on the adaptive immune system, particularly the B-cell compartment, in AML patients who are candidates for immunotherapy remains poorly understood. This gap is crucial because successful immunotherapy often relies on a robust immune response, which includes both cellular (T-cells) and humoral (B-cells) components. This paper aims to comprehensively assess the state of adaptive immunity in AML patients post-chemotherapy, using influenza vaccination as a functional test of immune recovery.

Methods

The researchers conducted a multi-faceted study on 10 AML patients in complete remission after chemotherapy and compared them to 10 age- and sex-matched healthy donors (HD).

  • Functional Immune Assessment: Patients were vaccinated with the seasonal influenza vaccine. Their antibody response was measured using a microneutralization assay and B-cell ELISPOT to assess antibody-secreting cells (ASCs).
  • Phenotypic Analysis: High-dimensional flow cytometry was used to comprehensively characterize various T-cell and B-cell populations, including their activation and differentiation states.
  • Genetic Analysis: Deep sequencing of the B-cell receptor (BCR) heavy chain (IGH) complementarity-determining region 3 (CDR3) was performed to assess the diversity and maturity of the B-cell repertoire.
  • Gene Expression Profiling: Microarray analysis was used to compare gene expression patterns between AML patients and HD to identify underlying molecular pathways.
  • Immune Checkpoint Expression: Cell surface immune checkpoint markers (PD-1, TIM3, CTLA4, 4-1BB) were assessed on CD8+ T-cells.

Datasets

The study utilized peripheral blood samples from 10 AML patients and 10 healthy donors. Microarray data was deposited in the Gene Expression Omnibus (GEO) under accession GSE97485.

Key Insights and Ideas

  • Uncoupled Immune Recovery: The most striking finding is the differential recovery of T-cell and B-cell immunity. While T-cells appear to regain function relatively quickly, B-cells show a much slower and incomplete reconstitution.
  • B-cell Immaturity and Dysfunction: AML patients post-chemotherapy exhibit a significantly higher proportion of immature/transitional B-cells and a marked reduction in memory B-cells, including those responsible for antibody responses. This suggests a failure to generate or retain antigen-experienced B-cells.
  • Antigen-Inexperienced B-cell Repertoire: BCR sequencing revealed that the B-cell repertoire in AML patients, particularly those closer to chemotherapy, is less mutated and appears "antigen-inexperienced," further supporting the idea of impaired affinity maturation.
  • Influenza Vaccination Failure: The observed B-cell abnormalities directly correlate with the poor response to influenza vaccination, with only 2 out of 10 patients achieving protective antibody titers.
  • T-cell Resilience: In contrast to B-cells, T-cell populations (CD3+, CD4+, CD8+) showed largely recovered frequencies and functional cytokine secretion in response to the influenza vaccine.
  • Immune Checkpoint Expression: Immune checkpoint marker expression (PD-1) on CD8+ T-cells was similar between AML patients and HD at baseline, but showed a trend towards decreasing frequency with increasing time since chemotherapy.

Key Results

  • Only 2 out of 10 AML patients seroconverted after influenza vaccination.
  • AML patients had significantly higher frequencies of transitional B-cells (35.5% vs. 15.5% in HD) and significantly lower frequencies of total memory B-cells (5.8% vs. 24.1% in HD).
  • Resting memory B-cell frequencies were drastically reduced in AML patients (1.71% vs. 18.5% in HD).
  • BCR sequencing showed no differences in overall clonality but suggested a less mutated repertoire in patients closer to chemotherapy.
  • All 5 patients assessed for T-cell function showed increases in influenza-specific cytokine secretion post-vaccination.
  • No significant differences were observed in the expression of PD-1, TIM3, CTLA4, and 4-1BB on CD8+ T-cells between AML patients and HD at baseline.

Limitations and Future Work

  • Small Sample Size: The study involved a small cohort of 10 AML patients, which limits the generalizability of the findings.
  • Heterogeneity: The AML patient cohort was diverse in terms of disease etiology, clinical outcomes, and time since chemotherapy, which contributed to observed variations.
  • Exclusion of Certain Markers: The study did not include markers like CD161 and ICOS in T-cell phenotyping, which have been implicated in immune responses.
  • Peripheral Blood Focus: The study focused on peripheral blood, and future work could compare immune cells in the bone marrow compartment with those in the blood.
  • Minimal Residual Disease (MRD): The potential impact of undetected AML blasts (MRD) on immune reconstitution was not addressed.

Future work could explore the implications of these findings for specific immunotherapies, such as immune checkpoint blockade, and investigate the role of T-regulatory cells and Th17 cells in B-cell recovery. The authors suggest that the observed uncoupled recovery of B-cell and T-cell immunity, along with increased PD-1 expression shortly after chemotherapy, may have significant implications for the success of various immunotherapeutic strategies.

Summary updated

Abstract

Our results suggest that while some aspects of cellular immunity recover quickly, humoral immunity is incompletely reconstituted in the year following intensive cytotoxic chemotherapy for AML. The observed B-cell abnormalities may explain the poor response to vaccination often seen in AML patients after chemotherapy. Furthermore, the uncoupled recovery of B-cell and T-cell immunity and increased PD-1 expression shortly after chemotherapy might have implications for the success of several modalities of immunotherapy.
BibTeX
@article{goswami2017impaired,
  author = {Meghali Goswami and Gabrielle T. Prince and Angélique Biancotto and Susan Moir and Lela Kardava and Brian H. Santich and Foo Cheung and Yuri Kotliarov and Jinguo Chen and Rongye Shi and Huizhi Zhou and Hana Golding and Jody Manischewitz and Lisa R. King and Lauren Kunz and Kimberly Noonan and Ivan Borrello and B. Douglas Smith and Christopher S. Hourigan},
  title = {{Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy}},
  journal = {Journal of Translational Medicine},
  year = {2017},
  doi = {10.1186/s12967-017-1252-2},
}
Figure